攝護腺癌荷爾蒙治療會增加乾癬發生的風險嗎?
柳瑞明1,2,3, 莊恆彰1, 許仁駿3
1衛生福利部桃園醫院 外科部 泌尿科;2國立陽明大學醫學系;3國防醫學院 生命科學研究所
Does androgen deprivation therapy increase the risk of psoriasis in patients with prostate cancer?
Jui-Ming Liu1,2,3, Heng-Chang Chuang1, Ren-Jun Hsu 3
1Division of Urology, Department of Surgery Taoyuan General Hospital, Ministry of Health and Welfare
2 Department of Medicine, National Yang-Ming University, Taipei, Taiwan
3 Graduate Institute of Life Sciences, National Defense Medical Center
Background:
Androgen deprivation therapy (ADT) use in prostate cancer (PCa) patients has been reported to exacerbate the course of psoriasis. To test the impact of ADT on the risk of psoriasis.
Methods:
We used data from the National Health Insurance Research Database of Taiwan between 1997 and 2013. There were 5141 ADT patients comprised the study group with 5141 matched non-ADT controls by propensity-score matched analysis. The demographic characteristics and comorbidities were used t test. Cox proportional hazards regression was used to calculate the hazard ratios (HR) for the risk of psoriasis.
Results:
Eighty-nine (0.87%) patients with newly diagnosed psoriasis were identified. Compared with non-ADT patients, ADT patients had a lower risk of subsequent psoriasis with an HR of 0.95 (95% confidence interval (CI) 0.63-1.45; P=0.816). A higher risk of psoriasis was observed in angiotensin-converting enzyme inhibitors patients (adjusted HR 2.14, 95% CI 1.09-4.20; P<0.05).
Conclusions:
ADT may not increase risk of psoriasis in PCa patients. Further studies are warranted to have fully investigation.